TRPV1 and metastatic carcinoma: In conclusion, in the presence of inflammatory metastatic carcinoma, doses of TRPV1 agonists high enough to activate TRPV1 in immune cells may have detrimental consequences; this effect may also partly explain the tumor-promoting action of TRPV1 agonists under certain conditions.